Literature DB >> 15166178

Statin therapy: having the good without the bad.

James K Liao.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15166178      PMCID: PMC2640840          DOI: 10.1161/01.HYP.0000126153.80112.5c

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  25 in total

1.  Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.

Authors:  M Sata; H Nishimatsu; E Suzuki; S Sugiura; M Yoshizumi; Y Ouchi; Y Hirata; R Nagai
Journal:  FASEB J       Date:  2001-09-17       Impact factor: 5.191

Review 2.  Breast cancer risk reduction: strategies for women at increased risk.

Authors:  Rowan T Chlebowski
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

4.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

5.  Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.

Authors:  Loïc Vincent; Claudine Soria; Farrokh Mirshahi; Paule Opolon; Zohair Mishal; Jean-Pierre Vannier; Jeannette Soria; Li Hong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

Review 6.  The statins as anticancer agents.

Authors:  Kelvin K W Chan; Amit M Oza; Lillian L Siu
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.

Authors:  Ho-Jin Park; Dequan Kong; Luisa Iruela-Arispe; Ulrike Begley; Dongjiang Tang; Jonas B Galper
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

Review 8.  Potential antitumor effects of statins (Review).

Authors:  Marek Jakobisiak; Jakub Golab
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

9.  Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells.

Authors:  Dirk H Walter; Kilian Rittig; Ferdinand H Bahlmann; Rudolf Kirchmair; Marcy Silver; Toshinori Murayama; Hiromi Nishimura; Douglas W Losordo; Takayuki Asahara; Jeffrey M Isner
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

10.  Statin use, hyperlipidaemia, and the risk of breast cancer.

Authors:  J A Kaye; C R Meier; A M Walker; H Jick
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

View more
  2 in total

1.  Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.

Authors:  T-C Chou; Y-F Lin; W-C Wu; K-M Chu
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

2.  Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation.

Authors:  Masood A Khan; Richard M Gallo; Gourapura J Renukaradhya; Wenjun Du; Jacquelyn Gervay-Hague; Randy R Brutkiewicz
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.